HC Wainwright Forecasts Aktis Oncology FY2025 Earnings

Aktis Oncology (NASDAQ:AKTS) – Research analysts at HC Wainwright issued their FY2025 earnings per share (EPS) estimates for Aktis Oncology in a report released on Monday, March 9th. HC Wainwright analyst R. Burns forecasts that the technology company will earn ($2.39) per share for the year. HC Wainwright has a “Buy” rating and a $30.00 price target on the stock. The consensus estimate for Aktis Oncology’s current full-year earnings is ($0.43) per share. HC Wainwright also issued estimates for Aktis Oncology’s Q4 2025 earnings at ($1.00) EPS, Q1 2026 earnings at ($0.64) EPS, Q2 2026 earnings at ($0.71) EPS, Q3 2026 earnings at ($0.77) EPS, Q4 2026 earnings at ($0.83) EPS, FY2026 earnings at ($2.95) EPS and FY2027 earnings at ($3.71) EPS.

AKTS has been the topic of a number of other research reports. Leerink Partners started coverage on shares of Aktis Oncology in a research report on Tuesday, February 3rd. They set an “outperform” rating and a $31.00 target price on the stock. Bank of America initiated coverage on shares of Aktis Oncology in a research report on Tuesday, February 3rd. They issued a “buy” rating and a $34.00 price target for the company. TD Cowen began coverage on Aktis Oncology in a research report on Tuesday, February 3rd. They set a “buy” rating on the stock. JPMorgan Chase & Co. started coverage on Aktis Oncology in a report on Tuesday, February 3rd. They issued an “overweight” rating and a $30.00 price objective for the company. Finally, Wall Street Zen upgraded Aktis Oncology to a “hold” rating in a research report on Saturday, January 17th. Five analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $31.25.

Aktis Oncology Stock Performance

Shares of NASDAQ AKTS opened at $19.41 on Wednesday. The business’s 50 day moving average price is $19.76. Aktis Oncology has a 1-year low of $16.80 and a 1-year high of $29.16.

Insider Activity at Aktis Oncology

In other Aktis Oncology news, major shareholder Vida Ventures Ii, Llc acquired 835,000 shares of the company’s stock in a transaction that occurred on Monday, January 12th. The stock was acquired at an average price of $18.00 per share, for a total transaction of $15,030,000.00. Following the acquisition, the insider directly owned 5,671,825 shares in the company, valued at $102,092,850. This represents a 17.26% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Helen Susan Kim bought 835,000 shares of Aktis Oncology stock in a transaction on Monday, January 12th. The shares were acquired at an average cost of $18.00 per share, for a total transaction of $15,030,000.00. Following the completion of the acquisition, the director directly owned 5,671,825 shares in the company, valued at approximately $102,092,850. The trade was a 17.26% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders purchased 6,117,776 shares of company stock valued at $110,119,968. Corporate insiders own 3.30% of the company’s stock.

Key Aktis Oncology News

Here are the key news stories impacting Aktis Oncology this week:

• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and set a $30 price target, which can act as a near-term bullish catalyst by drawing buy-side interest and framing upside vs. the current share price. HC Wainwright Note
• Neutral Sentiment: Recent short-interest reports show “0 shares” and a days-to-cover of 0.0 — this appears to be a reporting anomaly (NaN/inconsistent increases noted) and is not actionable until corrected data is posted. Short Interest Report
• Negative Sentiment: HC Wainwright’s published EPS forecasts project continued and widening losses over the next several years (examples: FY2025 EPS ≈ ($2.39); FY2026 ≈ ($2.95); FY2027 ≈ ($3.71); quarterly FY2026 losses also projected). Those loss projections highlight ongoing cash-burn and execution risk that could pressure valuation absent clear clinical or commercialization progress. EPS Estimates

About Aktis Oncology

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.